About Neurimmune Subone AG

Neurimmune Subone AG has been founded in 2007 and is part of the Neurimmune Group. For further information on Neurimmune, please visit www.neurimmune.com

Neurimmune Subone AG originally licensed aducanumab for the treatment and prevention of Alzheimer’s disease to Biogen in 2007 and regained global rights to the program in 2024. Aducanumab is a recombinant human monoclonal antibody targeting Abeta aggregates that are thought to play a role in the neurodegenerative process in Alzheimer’s disease. Aducanumab was granted FDA accelerated approval for the treatment of Alzheimer’s disease.

For further information on aducanumab, please visit www.neurimmune.com/aducanumab